id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-1656-0009,FDA,FDA-2025-P-1656,"Final Response Letter from FDA CDER to Pilnova Pharma, Inc.",Other,Grant of Petition,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,,2025-12-29T20:42:42Z,,0,0,09000064b9106bd6
FDA-2025-P-1656-0008,FDA,FDA-2025-P-1656,Completeness Assessment Correspondence,Other,Assessment Document or Analysis,2025-07-01T04:00:00Z,2025,7,2025-07-01T04:00:00Z,,2025-07-01T23:57:43Z,,0,0,09000064b8e4a86b
FDA-2025-P-1656-0006,FDA,FDA-2025-P-1656,Attachment 4,Supporting & Related Material,Background Material,2025-06-12T04:00:00Z,2025,6,,,2025-06-12T23:25:53Z,,0,0,09000064b8dfaf8f
FDA-2025-P-1656-0004,FDA,FDA-2025-P-1656,Attachment 2,Supporting & Related Material,Background Material,2025-06-12T04:00:00Z,2025,6,,,2025-06-12T23:25:23Z,,0,0,09000064b8dfaf8d
FDA-2025-P-1656-0003,FDA,FDA-2025-P-1656,Attachment 1 - Approved Drug Products with Therapeutic Equivalence Evaluation (Electronic Orange Book),Supporting & Related Material,Background Material,2025-06-12T04:00:00Z,2025,6,,,2025-06-12T23:24:58Z,,0,0,09000064b8dfaf8c
FDA-2025-P-1656-0005,FDA,FDA-2025-P-1656,Attachment 3,Supporting & Related Material,Background Material,2025-06-12T04:00:00Z,2025,6,,,2025-06-12T23:25:38Z,,0,0,09000064b8dfaf8e
FDA-2025-P-1656-0002,FDA,FDA-2025-P-1656,Acknowledgment Letter from FDA DDM to Pilnova Pharma Inc.,Other,Acknowledgement Letter/Receipt,2025-06-12T04:00:00Z,2025,6,2025-06-12T04:00:00Z,,2025-06-12T23:24:39Z,,0,0,09000064b8dfaf8a
FDA-2025-P-1656-0007,FDA,FDA-2025-P-1656,Attachment 5,Supporting & Related Material,Background Material,2025-06-12T04:00:00Z,2025,6,,,2025-06-12T23:26:08Z,,0,0,09000064b8dfaf90
FDA-2025-P-1656-0001,FDA,FDA-2025-P-1656,Suitability Petition from Pilnova Pharma Inc.,Other,Petition(s),2025-06-12T04:00:00Z,2025,6,2025-06-12T04:00:00Z,,2025-12-24T01:28:46Z,,0,0,09000064b8df686a